November 1, 2022

Dear Colleague,

On October 19, 2022, the Centers for Disease Control and Prevention (CDC) signed a decision memo allowing Novavax monovalent COVID-19 boosters for people ages 18 years and older. This follows Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). Novavax is a protein subunit vaccine. Guidance for use of Novavax monovalent boosters has been added to CDC’s Interim Clinical Considerations.

A Novavax monovalent booster dose may be used instead of an mRNA bivalent booster dose in limited situations in people ages 18 years and older who completed any FDA-approved or FDA-authorized primary series, have not received any previous booster doses, and are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The authorized dosage is 0.5 mL administered intramuscularly at least 6 months after completion of a primary series.

Providers who are interested in ordering Novavax vaccine should email covidvax@health.nyc.gov. Ordering for Novavax is not available on the Online Registry. The Novavax product used for the primary series is the same product used for booster doses.

Patients can locate facilities offering Novavax vaccine (including Novavax booster doses) by visiting vaccinefinder.nyc.gov.

Thank you for continuing to promote and protect the health of New Yorkers through vaccination.

Sincerely,

Bindy Crouch, MD, MPH
Medical Director
Immunization Infrastructure and Clinical Support Unit
Bureau of Immunization